New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareBronchogen vs MK-677 (Ibutamoren)

Bronchogen vs MK-677 (Ibutamoren)

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Bronchogen
Growth Hormone Peptides
MK-677 (Ibutamoren)
Summary
Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
Half-Life
Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
24 hours
Admin Route
SubQ, Oral
Oral
Research
Typical Dose
10 mg per day
10–25 mg
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Tissue-specific support for bronchial and lung health
  • Promotes normalization of bronchial epithelial cell function
  • Potential benefits in chronic bronchitis and COPD support
  • Anti-aging effects on pulmonary tissue
  • May reduce frequency of respiratory infections
  • Supports lung function preservation with aging
  • Compatible with other Khavinson bioregulator peptides
  • Increases lean muscle mass
  • Enhances bone density
  • Improves sleep quality and REM sleep
  • Accelerates recovery from training
  • Increases appetite
  • May improve skin elasticity and appearance
  • Supports fat loss while maintaining muscle
  • Oral administration — no injections required
  • 24-hour half-life allows once-daily dosing
Side Effects
  • Generally well tolerated in research studies
  • Mild local reactions at injection site (if injected)
  • No significant systemic side effects reported at standard doses
  • Increased appetite (significant in some users)
  • Water retention and puffiness
  • Elevated blood glucose / insulin resistance (monitor in diabetics)
  • Lethargy initially
  • +2 more
Stacks With